Lung Cancer

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Treatment with the investigational agent dacomitinib improved PFS when compared with erlotinib in patients with non–small cell lung cancer experiencing progression during chemotherapy.

Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.

The expansion of testing for genetic abnormalities in patients with advanced lung cancer is generating questions about which patients' tumors should be tested, how they should be tested, and whether they should be retested.

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

Nearly 2 years after a landmark study supported CT for people at high risk of developing lung cancer, questions persist about the complexities of implementing an early detection program.

The addition of sorafenib to first-line gemcitabine/cisplatin does not appear to lengthen survival in patients with advanced, nonsquamous, non–small cell lung cancer.

As Bonnie Addario has gone from patient to survivor, she has learned much about what patients are looking for in terms of information and care.

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

The phase III MARQUEE trial examining tivantinib has been halted following a planned interim analysis because it was not expected to meet its primary endpoint.

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.

Lung cancer survivor, Bonnie Addario, the founder of the Bonnie J. Addario Lung Cancer Foundation, discusses the prevalent stigma that lung cancer is a self-inflicted disease caused solely by smoking.

Dr. David Spigel, from the Sarah Cannon Research Institute, discusses the rapidly evolving non-small cell lung cancer treatment landscape.

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.

A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Eli Lilly announced that a combination regimen of their chemotherapy drug Alimta and Avastin failed to improve survival in late stage non-squamous non-small cell lung cancer.

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.